Antibody & AOC CDMO
The development and commercialization of next-generation antibody therapeutics require comprehensive expertise across molecular design, process development, analytical characterization, GMP manufacturing, and regulatory compliance. Protheragen provides integrated Antibody CDMO and Antibody-Oligonucleotide Conjugate (AOC) CDMO services, supporting pharmaceutical and biotechnology companies from early-stage development through commercial manufacturing. With multidisciplinary capabilities covering antibody engineering, conjugation technology, CMC development, analytical testing, and GMP production, we provide flexible and scalable solutions to accelerate the development of innovative antibody-based therapies.
Overview of Antibody & AOC CDMO
Antibody and antibody-oligonucleotide conjugate (AOC) therapies represent rapidly evolving areas in modern biopharmaceutical development. While monoclonal antibodies have become established therapeutic platforms, AOCs combine the targeted delivery capability of antibodies with the therapeutic potential of oligonucleotides, creating new opportunities for precision medicine.
The development of antibody-based therapeutics requires coordinated optimization of molecular properties, expression systems, manufacturing processes, and quality attributes. For AOC molecules, additional challenges including conjugation efficiency, drug-to-antibody ratio (DAR), molecular stability, and product characterization require specialized technical expertise.
An integrated Antibody & AOC CDMO platform enables efficient transition from discovery research to clinical development and commercial supply by providing:
- Antibody sequence optimization and engineering support
- Cell line development and expression optimization
- Upstream and downstream process development
- Antibody conjugation process development
- Analytical method development and characterization
- GMP drug substance manufacturing
- Drug product formulation and fill-finish
- Commercial manufacturing support
Fig.1 Developmental timeline and key milestones of antibody-oligonucleotide conjugates. (Li M, et al., 2025)
Our Services
Protheragen offers comprehensive development and manufacturing solutions designed to support antibody therapeutics and AOC programs throughout the entire product lifecycle. From early feasibility studies to GMP commercial production, our integrated platform helps partners reduce development risks, optimize manufacturing processes, and accelerate regulatory advancement.
Early evaluation and strategic planning are essential for successful antibody and AOC development. Protheragen provides comprehensive candidate assessment and CMC strategy services to evaluate molecular properties, developability risks, manufacturing feasibility, and regulatory requirements. By integrating scientific evaluation with CMC planning, we help identify promising candidates and establish optimized development strategies for IND and BLA submissions.
Related services include:
A high-performance cell line is critical for efficient and scalable antibody production. Protheragen provides cell line construction, screening, and library building services to support the generation and selection of stable, high-producing expression systems. Our expertise in mammalian expression platforms enables the development of cell lines with improved productivity, stability, and manufacturing potential for antibody therapeutics.
Protheragen offers cell culture process development services to optimize antibody expression and improve production efficiency. Our capabilities include upstream process development, media optimization, feeding strategy development, and process parameter optimization using scalable bioreactor systems. These services help establish robust and reproducible manufacturing processes suitable for clinical and commercial production.
Efficient purification processes are essential for achieving high-quality antibody and AOC products. Protheragen provides downstream process development services including purification strategy development, chromatography optimization, impurity removal, and process scalability evaluation. Our integrated approach supports the production of highly purified therapeutic proteins with consistent quality attributes.
Preparation process development focuses on optimizing formulation and manufacturing processes to ensure product stability, safety, and performance. Protheragen provides formulation development, buffer optimization, stability evaluation, and process optimization services for antibody and AOC therapeutics. Our solutions support the transition from laboratory-scale preparation to clinical and commercial manufacturing.
Comprehensive analytical methods are essential for characterizing antibody and AOC products and ensuring quality control throughout development. Protheragen provides analytical method development services covering structural characterization, purity analysis, potency evaluation, impurity detection, stability studies, and comparability assessment. These analytical solutions support regulatory submissions and lifecycle management of complex biologics.
Protheragen provides GMP commercial manufacturing solutions for antibody and AOC therapeutics, supporting the transition from clinical development to large-scale production. Our commercial manufacturing capabilities include drug substance manufacturing, drug product manufacturing, process validation, technology transfer, and long-term supply support. With flexible production platforms and quality-focused manufacturing systems, we help partners achieve reliable and compliant commercial production.
Integrated Antibody & AOC Development Workflow
The development of antibody therapeutics and antibody-oligonucleotide conjugates requires seamless integration of multiple disciplines, including molecular design, process development, analytical characterization, and GMP manufacturing. Protheragen provides an integrated CDMO workflow that supports every stage of product development, enabling efficient progression from early candidate evaluation to commercial supply.
| Development Stage |
Key Activities |
| Candidate Assessment |
Developability evaluation, molecular characterization, CMC strategy |
| Cell Line Development |
Cell line construction, screening, expression optimization |
| Process Development |
Upstream and downstream process optimization |
| Preparation Development |
Formulation optimization and stability evaluation |
| Analytical Development |
Product characterization and quality assessment |
| Clinical Manufacturing |
GMP drug substance and drug product manufacturing |
| Commercial Manufacturing |
Process validation and commercial supply |
This integrated approach helps reduce development risks, improve manufacturing consistency, and accelerate regulatory progression.
Antibody & AOC Technical Platforms
Successful development of antibody and AOC therapeutics requires advanced technologies for molecular evaluation, process optimization, and product characterization. Protheragen combines multidisciplinary expertise and advanced platforms to support complex biologics development.
Antibody Engineering Platform
- Recombinant antibody expression
- Antibody optimization and screening
- Molecular property evaluation
- Functional characterization
Cell Line Development Platform
- Mammalian expression systems
- Stable cell line generation
- High-producing clone screening
- Cell bank establishment
Bioprocess Development Platform
- Upstream process optimization
- Bioreactor scale-up
- Purification process development
- Process characterization
AOC Conjugation Platform
- Antibody preparation
- Oligonucleotide conjugation strategy
- Linker optimization
- Conjugation efficiency evaluation
Analytical Characterization Platform
- Protein structure analysis
- Purity and impurity profiling
- Aggregation analysis
- Stability evaluation
Quality & Regulatory Support
Regulatory compliance and product quality management are fundamental to successful antibody and AOC development. Protheragen integrates quality systems into every stage of development and manufacturing.
Our quality and regulatory support includes:
- Quality management system (QMS)
- GMP compliance support
- Regulatory documentation preparation
- IND/BLA CMC support
- Process validation documentation
- Regulatory inspection readiness
These capabilities help ensure smooth regulatory advancement and successful commercialization.
Applications of Antibody and AOC Therapeutics
Antibody-based therapeutics have become important platforms for targeted treatment across multiple disease areas. The combination of antibodies with advanced payload technologies further expands therapeutic possibilities. Protheragen supports development programs including:
Oncology
- Targeted antibody therapies
- Antibody-drug conjugate related platforms
- Precision cancer therapeutics
Immunology
- Immune modulation therapies
- Cytokine and immune pathway targeting
Rare Diseases
- Targeted molecular therapies
- Precision medicine approaches
Genetic and Molecular Medicine
- Antibody-guided oligonucleotide delivery
- RNA-targeting therapeutic strategies
Why Choose Protheragen
- Integrated End-to-End Development
From candidate evaluation to commercial manufacturing, Protheragen provides complete lifecycle support.
- Expertise in Complex Biologics
Our teams combine antibody engineering, biologics manufacturing, and oligonucleotide technologies to support advanced therapeutic platforms.
- Flexible Development Solutions
Customized solutions are available for early research programs, clinical-stage products, and commercial manufacturing needs.
Comprehensive quality systems and regulatory-focused processes ensure reliable product development and manufacturing.
The development of antibody and antibody-oligonucleotide conjugate (AOC) therapeutics requires a comprehensive approach that integrates molecular assessment, CMC strategy, process development, analytical characterization, and GMP manufacturing. Protheragen provides an integrated Antibody & AOC CDMO platform to support the entire product lifecycle, from early candidate evaluation to commercial production. With expertise across antibody engineering, bioprocess development, conjugation technologies, quality control, and regulatory support, we help biotechnology and pharmaceutical companies overcome development challenges and accelerate the advancement of next-generation antibody-based therapies. Through flexible and scalable solutions, Protheragen is committed to delivering reliable development and manufacturing support for innovative biologics and targeted therapeutic platforms. Contact us to discuss your antibody or AOC development program and explore how our integrated CDMO capabilities can support your next-generation therapeutic innovation.
Reference
- Li M, et al. "Advances in the pharmaceutical development of antibody-oligonucleotide conjugates" European Journal of Pharmaceutical Sciences. 2025; 215:107292.
